Colin Hayward currently serves as the Head of Medical Science at Ergomed Clinical Research, bringing over 25 years of experience in oncology drug development. Before joining Ergomed, Colin was the Chief Medical Officer for Telix, a radiopharmaceutical company. He is a specialized pharmaceutical physician with the UK Faculty of Pharmaceutical Medicine. Throughout his career, Colin has worked on major brands like Rituxan and Avastin and recently specialized in radiopharmaceuticals. Colin is dedicated to expanding patient access to innovative treatments in his current role. His leadership supports his global medical team’s mission of combining science and commerce to create development programs that meet patients’ needs. Colin also serves on the Clinical Advisory Board for GlyTherix. Based in North Carolina, Colin is an avid Carolina Hurricanes hockey fan. He obtained his medical degree from Guys and St Thomas’s Hospital in London.